Xyphos Biosciences - Ownership and Business Overview

Life ScienceCompany

Xyphos Biosciences Ownership

Who owns Xyphos Biosciences?

Xyphos Biosciences is owned by Astellas Pharma. It was acquired on December 26, 2019.

Xyphos Biosciences Business Overview

Where is Xyphos Biosciences headquartered?

Xyphos Biosciences is headquartered in South San Francisco, California.

What sector is Xyphos Biosciences in?

Xyphos Biosciences is a life science company.

Life Science M&A Summary in 2019

Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2019. The largest life science acquisition in 2019 was Celgene - which was acquired by Bristol-Myers Squibb for $74.0B.

Join Mergr to view all 249 acquisitions of life science companies in 2019, including 44 acquisitions by private equity firms, and 205 by strategics.

Xyphos Biosciences, Inc.

100 Kimball Way,
South San Francisco, California 94080
United States,
(650) 243-2951
www.xyphosinc.com

Xyphos Biosciences, Inc. is a privately held development-stage biotechnology company, is focused on the creation and development of immuno-oncology therapeutics designed to harness the power of the patient's immune system to cure cancer. Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform allow new and potentially better ways to mobilize and control immune cells to find and destroy specifically targeted cells throughout the body.


 Subscribe to unlock this and 207,390
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.